Marker Therapeutics Inc. (MRKR) is priced at $2.22 after the most recent trading session. At the very opening of the session, the stock price was $2.20 and reached a high price of $2.44, prior to closing the session it reached the value of $2.36. The stock touched a low price of $2.15.
Recently in News on April 29, 2021, Marker Therapeutics to Host First Quarter 2021 Operating and Financial Results Conference Call and Webcast on Wednesday, May 12, 2021. Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that it will host a conference call and webcast on Wednesday, May 12, 2021 at 5:00 p.m. Eastern Time to review its first quarter 2021 financial and operating results and provide a corporate update. You can read further details here
Marker Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $3.77 on 02/09/21, with the lowest value was $1.41 for the same time period, recorded on 01/04/21.
Marker Therapeutics Inc. (MRKR) full year performance was -4.84%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Marker Therapeutics Inc. shares are logging -40.98% during the 52-week period from high price, and 68.56% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.32 and $3.77.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1489117 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Marker Therapeutics Inc. (MRKR) recorded performance in the market was 62.76%, having the revenues showcasing -22.37% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 195.12M, as it employees total of 44 workers.
The Analysts eye on Marker Therapeutics Inc. (MRKR)
During the last month, 0 analysts gave the Marker Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 2.20, with a change in the price was noted +0.67. In a similar fashion, Marker Therapeutics Inc. posted a movement of +41.61% for the period of last 100 days, recording 2,593,772 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for MRKR is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical rundown of Marker Therapeutics Inc. (MRKR)
Raw Stochastic average of Marker Therapeutics Inc. in the period of last 50 days is set at 32.89%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 47.92%. In the last 20 days, the company’s Stochastic %K was 49.31% and its Stochastic %D was recorded 50.69%.
Considering, the past performance of Marker Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 62.76%. Additionally, trading for the stock in the period of the last six months notably improved by 62.76%, alongside a downfall of -4.84% for the period of the last 12 months. The shares increased approximately by -4.45% in the 7-day charts and went down by 14.01% in the period of the last 30 days. Common stock shares were lifted by -22.37% during last recorded quarter.